Characteristics of Anaplastic Oligodendrogliomas Short-Term Survivors: A POLA Network Study.
Karnofsky Performance Status
age
anaplastic oligodendroglioma
chemotherapy
proliferation
radiotherapy
seizure
surgery
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
06 05 2022
06 05 2022
Historique:
received:
10
06
2021
accepted:
22
12
2021
entrez:
6
5
2022
pubmed:
7
5
2022
medline:
11
5
2022
Statut:
ppublish
Résumé
Anaplastic oligodendrogliomas IDH-mutant and 1p/19q codeleted (AO) occasionally have a poor outcome. Herein we aimed at analyzing their characteristics. We retrospectively analyzed the characteristics of 44 AO patients with a cancer-specific survival <5 years (short-term survivors, STS) and compared them with those of 146 AO patients with a survival ≥5 years (classical survivors, CS) included in the POLA network. Compared to CS, STS were older (P = .0001), less frequently presented with isolated seizures (P < .0001), more frequently presented with cognitive dysfunction (P < .0001), had larger tumors (P = .= .003), a higher proliferative index (P = .= .0003), and a higher number of chromosomal arm abnormalities (P = .= .02). Regarding treatment, STS less frequently underwent a surgical resection than CS (P = .= .0001) and were more frequently treated with chemotherapy alone (P = .= .009) or with radiotherapy plus temozolomide (P = .= .05). Characteristics independently associated with STS in multivariate analysis were cognitive dysfunction, a number of mitosis > 8, and the absence of tumor resection. Based on cognitive dysfunction, type of surgery, and number of mitosis, patients could be classified into groups of standard (18%) and high (62%) risk of <5 year survival. The present study suggests that although STS poor outcome appears to largely result from a more advanced disease at diagnosis, surgical resection may be particularly important in this population.
Sections du résumé
BACKGROUND
Anaplastic oligodendrogliomas IDH-mutant and 1p/19q codeleted (AO) occasionally have a poor outcome. Herein we aimed at analyzing their characteristics.
METHODS
We retrospectively analyzed the characteristics of 44 AO patients with a cancer-specific survival <5 years (short-term survivors, STS) and compared them with those of 146 AO patients with a survival ≥5 years (classical survivors, CS) included in the POLA network.
RESULTS
Compared to CS, STS were older (P = .0001), less frequently presented with isolated seizures (P < .0001), more frequently presented with cognitive dysfunction (P < .0001), had larger tumors (P = .= .003), a higher proliferative index (P = .= .0003), and a higher number of chromosomal arm abnormalities (P = .= .02). Regarding treatment, STS less frequently underwent a surgical resection than CS (P = .= .0001) and were more frequently treated with chemotherapy alone (P = .= .009) or with radiotherapy plus temozolomide (P = .= .05). Characteristics independently associated with STS in multivariate analysis were cognitive dysfunction, a number of mitosis > 8, and the absence of tumor resection. Based on cognitive dysfunction, type of surgery, and number of mitosis, patients could be classified into groups of standard (18%) and high (62%) risk of <5 year survival.
CONCLUSION
The present study suggests that although STS poor outcome appears to largely result from a more advanced disease at diagnosis, surgical resection may be particularly important in this population.
Identifiants
pubmed: 35522558
pii: 6542926
doi: 10.1093/oncolo/oyac023
pmc: PMC9074983
doi:
Substances chimiques
Temozolomide
YF1K15M17Y
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
414-423Informations de copyright
© The Author(s) 2022. Published by Oxford University Press.
Références
Neuro Oncol. 2016 Nov;18(11):1529-1537
pubmed: 27370396
J Clin Oncol. 2002 Apr 15;20(8):2076-84
pubmed: 11956268
Sci Rep. 2020 Nov 19;10(1):20162
pubmed: 33214617
PLoS One. 2012;7(10):e45950
pubmed: 23071531
Brain. 2014 Feb;137(Pt 2):449-62
pubmed: 24374407
Hum Pathol. 2010 Jun;41(6):815-23
pubmed: 20303140
J Neurooncol. 2020 Jan;146(1):121-130
pubmed: 31741234
Neuro Oncol. 2014 May;16(5):662-70
pubmed: 24353325
J Clin Oncol. 2013 Jan 20;31(3):344-50
pubmed: 23071237
Acta Neuropathol Commun. 2018 Sep 7;6(1):89
pubmed: 30193580
Neuro Oncol. 2017 Aug 01;19(8):1127-1134
pubmed: 28201752
NPJ Precis Oncol. 2018 Nov 6;2:24
pubmed: 30417117
Acta Neuropathol. 2016 Oct;132(4):625-34
pubmed: 27573687
J Clin Oncol. 2013 Jan 20;31(3):337-43
pubmed: 23071247
J Neurooncol. 2015 Oct;125(1):207-15
pubmed: 26341368
Neuro Oncol. 2017 Jun 1;19(6):786-795
pubmed: 28340142
Neuro Oncol. 2019 Sep 6;21(9):1164-1174
pubmed: 31140557
Oncologist. 2018 Dec;23(12):1500-1510
pubmed: 30018130
Neuro Oncol. 2021 Mar 25;23(3):457-467
pubmed: 32678879
Brain Pathol. 2020 May;30(3):465-478
pubmed: 31561286
Neuro Oncol. 2014 Sep;16(9):1244-54
pubmed: 24723566
Neuro Oncol. 2017 Nov 6;19(suppl_5):v1-v88
pubmed: 29117289
Nat Commun. 2016 Apr 19;7:11263
pubmed: 27090007
Neuro Oncol. 2019 Dec 17;21(12):1519-1528
pubmed: 31832685
Acta Neuropathol. 2018 Jul;136(1):153-166
pubmed: 29687258
Neuro Oncol. 2018 Jan 10;20(1):66-77
pubmed: 29016839
PLoS One. 2017 Nov 29;12(11):e0188419
pubmed: 29186201
Neuro Oncol. 2020 Jul 7;22(7):993-1005
pubmed: 32025725
Neuro Oncol. 2014 Nov;16(11):1541-6
pubmed: 24997140
Clin Transl Radiat Oncol. 2018 Dec 31;15:46-52
pubmed: 30656222
J Neurooncol. 2019 Sep;144(3):591-601
pubmed: 31407129
Oncotarget. 2017 May 30;8(22):35523-35531
pubmed: 28388591
PLoS One. 2019 Jan 30;14(1):e0211513
pubmed: 30699183
Neuro Oncol. 2011 Jun;13(6):649-59
pubmed: 21636710
Ann Neurol. 2003 Apr;53(4):524-8
pubmed: 12666121
Neurology. 2017 May 9;88(19):1805-1813
pubmed: 28404805
Histopathology. 2012 May;60(6):885-94
pubmed: 22335622
Neuro Oncol. 2016 Jun;18(6):888-90
pubmed: 27175000
J Neurosurg. 2020 Jun 05;134(5):1675
pubmed: 32502995
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931